RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Hiroshi Matsui and Olorunseun Ogunwobi.
Hiroshi Matsui
Connection Strength
0.443
Olorunseun Ogunwobi
  1. Awah CU, Mun JS, Paragodaarachchi A, Boylu B, Ochu C, Matsui H, Ogunwobi OO. The Engineered Drug 3'UTRMYC1-18 Degrades the c-MYC-STAT5A/B-PD-L1 Complex In Vivo to Inhibit Metastatic Triple-Negative Breast Cancer. Cancers (Basel). 2024 Jul 26; 16(15).
    View in: PubMed
    Score: 0.224
  2. Awah CU, Sun Mun J, Paragodaarachchi A, Boylu B, Nzegwu M, Matsui H, Ogunwobi O. Nanocage-incorporated engineered destabilized 3'UTR ARE of ERBB2 inhibits tumor growth and liver and lung metastasis in EGFR T790M osimertinib- and trastuzumab-resistant and ERBB2-expressing NSCLC via the reduction of ERBB2. Front Oncol. 2024; 14:1344852.
    View in: PubMed
    Score: 0.219
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support